Repligen Co. (NASDAQ:RGEN) Stake Increased by Alliance Wealth Advisors LLC UT

Alliance Wealth Advisors LLC UT grew its holdings in Repligen Co. (NASDAQ:RGEN) by 4.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,460 shares of the biotechnology company’s stock after purchasing an additional 114 shares during the period. Alliance Wealth Advisors LLC UT’s holdings in Repligen were worth $442,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the business. Artisan Partners Limited Partnership lifted its holdings in shares of Repligen by 11.3% in the third quarter. Artisan Partners Limited Partnership now owns 1,556,873 shares of the biotechnology company’s stock valued at $247,558,000 after purchasing an additional 157,807 shares in the last quarter. Wellington Management Group LLP lifted its holdings in shares of Repligen by 2.1% in the third quarter. Wellington Management Group LLP now owns 1,396,610 shares of the biotechnology company’s stock valued at $222,075,000 after purchasing an additional 29,215 shares in the last quarter. Bank of New York Mellon Corp increased its stake in shares of Repligen by 13.0% in the third quarter. Bank of New York Mellon Corp now owns 1,195,629 shares of the biotechnology company’s stock worth $190,117,000 after acquiring an additional 137,220 shares during the last quarter. Conestoga Capital Advisors LLC increased its stake in shares of Repligen by 0.4% in the fourth quarter. Conestoga Capital Advisors LLC now owns 709,738 shares of the biotechnology company’s stock worth $127,611,000 after acquiring an additional 2,590 shares during the last quarter. Finally, Parnassus Investments LLC acquired a new position in shares of Repligen in the third quarter worth $87,475,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Repligen Stock Up 0.6 %

Repligen stock traded up $0.92 during mid-day trading on Friday, hitting $166.58. 341,269 shares of the company’s stock were exchanged, compared to its average volume of 463,708. The company has a current ratio of 7.02, a quick ratio of 5.75 and a debt-to-equity ratio of 0.26. The stock has a market cap of $9.30 billion, a P/E ratio of 231.36, a P/E/G ratio of 5.46 and a beta of 1.02. Repligen Co. has a 1-year low of $110.45 and a 1-year high of $211.13. The stock has a 50 day moving average of $184.21 and a two-hundred day moving average of $173.68.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings results on Wednesday, February 21st. The biotechnology company reported $0.33 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.33. Repligen had a return on equity of 5.00% and a net margin of 6.51%. The company had revenue of $155.74 million for the quarter, compared to the consensus estimate of $155.38 million. During the same period last year, the business posted $0.68 earnings per share. The firm’s revenue was down 16.6% compared to the same quarter last year. As a group, analysts anticipate that Repligen Co. will post 1.46 EPS for the current fiscal year.

Insider Transactions at Repligen

In other news, CEO Anthony Hunt sold 16,707 shares of the firm’s stock in a transaction that occurred on Friday, March 8th. The shares were sold at an average price of $197.44, for a total transaction of $3,298,630.08. Following the completion of the sale, the chief executive officer now owns 185,249 shares of the company’s stock, valued at $36,575,562.56. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In related news, Director Karen A. Dawes sold 1,000 shares of the firm’s stock in a transaction that occurred on Tuesday, February 27th. The shares were sold at an average price of $193.35, for a total value of $193,350.00. Following the completion of the sale, the director now owns 87,367 shares of the company’s stock, valued at $16,892,409.45. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Anthony Hunt sold 16,707 shares of the firm’s stock in a transaction that occurred on Friday, March 8th. The shares were sold at an average price of $197.44, for a total transaction of $3,298,630.08. Following the completion of the sale, the chief executive officer now directly owns 185,249 shares of the company’s stock, valued at approximately $36,575,562.56. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 25,597 shares of company stock valued at $5,039,532. Corporate insiders own 1.20% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on RGEN. KeyCorp upped their price target on shares of Repligen from $210.00 to $220.00 and gave the stock an “overweight” rating in a research note on Thursday, February 15th. Stifel Nicolaus upped their price target on shares of Repligen from $165.00 to $207.00 and gave the stock a “buy” rating in a research note on Thursday, February 22nd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat, Repligen presently has a consensus rating of “Moderate Buy” and an average price target of $196.70.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.